The role of leukotrienes in asthma and allergic rhinitis

Clinical and Experimental Allergy

Volumn 26, Issue 8, 1996, Pages 868-879

  Busse, W W ^a  

^a University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NEDOCROMIL SODIUM; SALBUTAMOL; ZAFIRLUKAST; ZILEUTON;

ALLERGIC RHINITIS; ASTHMA; CLINICAL TRIAL; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029778813     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.1996.tb00621.x     Document Type: Review

References (75)

1. Feldberg W, Kellaway CH. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol 1938; 94:187-226.
2. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983; 220:568-75.
3. Henderson WR. The role of leukotrienes in inflammation. Ann Intern Med 1994; 121:684-97.
4. White MV, Kaliner MA. Mediators of allergic rhinitis. J Allergy Clin Immunol 1992; 90:699 704.
5. 4) in human skin. J Invest Dermatol 1983; 80:115-9.
6. 4 on the microvasculature of guinea pigs. Prostaglandins 1981; 21:315 21.
7. 4 on mucin release into the cat trachea in vivo and in vitro. Br J Pharmacol 1982; 77:391 3.
8. 4: comparison of potency in canine trachea in vivo. Prostaglandins 1983; 25:237-43.
9. Yanni JM, Foxwell MH, Whitman LL, Smith WL, Nolan JC. Effect of intravenously administered lipoxygenase metabolites on rat tracheal mucous gel layer thickness. Int Arch Allergy Appl Immunol 1989; 90:307 9.
10. 4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982; 126:449 51.
11. Dahlen S-E, Hedqvist P, Hammarstrom S, Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature 1980; 288:484 6.
12. 4 in humans. Am Rev Respir Dis 1985; 131:368 72.
13. 4 in normal and asthmatic subjects. Eur Respir J 1988; 1:913 7.
14. 4 and platelet-activating factor on airway reactivity in normal subjects. Am Rev Respir Dis 1990; 141:993 7.
15. 4 is a potent and stereospecific stimulator of neutrophil chemotaxis and adherence. Blood 1981; 58:658 63.
16. 4. Br Med Bull 1983; 39:249 54.
17. 4 and granulocytic infiltration into asthmatic airways. Lancet 1993; 341:989-90.
18. 4 in bronchoalveolar lavage in bronchial asthma and other diseases. J Allergy Clin Immunol 1989; 84:19-26.
19. 4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 1990; 142:112 9.
20. 4 levels after allergen and exercise challenge in bronchial asthma. Am Rev Respir Dis 1991; 144: 1411 3.
21. Dahlen B, Kumlin M, Margolskee JJ et al. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J 1993; 6:1018 26.
22. Pipkorn U, Proud D, Lichlenstein LM et al. Effect of short-term systemic glucocorticoid treatment on human nasal mediator release after antigen challenge. J Clin Invest 1987; 80:957 61.
23. Knani J, Campbell A, Enander I et al. Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis. J Allergy Clin Immunol 1992; 90:880 9.
24. 4 release in upper respiratory mucosa during natural exposure to ragweed in ragweed-sensitive children. J Allergy Clin Immunol 1988; 82:414 8.
25. Ophirh C, Fink A, Eliraz A, Tabachnik E, Bentwich Z. Allergen-induced leukotriene production by nasal mucosa and peripheral blood leukocytes. Arch Otolaryngol Head Neck Surg 1988; 114:522 4.
26. Meslier T, Braunstein J, Lacroniqaue J et al. Local cellular and humoral responses to antigenic and distilled water challenge in subjects with allergic rhinitis. Am Rev Respir Dis 1988; 137:617 24.
27. Wang D, Clement P, Smitz J, Derde MP. Concentrations of chemical mediators in nasal secretions of patients with hay fever during natural allergen exposure. Acta Otolaryngol 1994; 114:552.
28. 4 in allergic rhinitis. Allergy 1985; 40: 1 6.
29. Rovati GE, Giovanazzi S, Mezzetti M, Nicosia S. Heterogeneity of binding sites for ICI: 198:615 in human lung parenchyma. Biochem Pharmacol 1992; 44:1411 5.
30. Drazen JM. Leukotrienes in asthma and rhinitis In: Busse WW. Rolgate, eds. Asthma and Rhinitis. Oxford: Blackwell Science Ltd, 1994.
31. 4 in the guinea pig lung. Biochem Biophys Res Commun 1983; 116:1136 43.
32. 4 binding to rat lung membranes. J Biol Chem 1983; 258:9616 9.
33. 4. J Pharmacol Exp Ther 1986; 237:558 62.
34. Drazen JM. Comparative contractile responses to sulfidopeptide leukotrienes in normal and asthmatic human subjects. Ann NY Acad Sci 1988; 524:289 97.
35. Ellis JL, Undem BJ. Role of peptidoleukotrienes in capsaicinsensitive sensory fiber-mediated responses in guinea pig airways. J Physiol 1991; 436:469 84.
36. 4 on nasal mucosal blood flow. nasal airway resistance, and nasal secretion in humans. Clin Allergy 1986; 60:289 97.
37. 4 in allergic rhinitis. Ann Allergy 1988; 60: 537 40.
38. Serra-Batlles J, Montserrat JM, Mullol J et al. Response of the nose to exercise in healthy subjects and in patients with rhinitis and asthma. Thorax 1994; 49:128 32.
39. Rand C, Wise R, Nides M et al. Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis 1992; 146:1559 64.
40. Hussar DA. Importance of patient compliance in effective antimicrobial therapy. Pediatr Infect Dis J 1987; 6:971 5.
41. Knapp HR. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med 1990; 323:1745 8.
42. Flowers BK, Proud D, Kagey-Sobotka A. Lichtenstein LM, Naclerio RM. The effect of a leukotriene antagonist on the early response to antigen. Otolaryngol Head Neck Surg 1990; 102:219 24.
43. Fischer AR, Rosenberg MA. Lilly CM et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 1994; 94:1046 56.
44. 4-receptor antagonist. ICI; 204:219. relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995; 151:1734 9.
45. 4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI-204, 219. Clin Pharmacol Therapeut 1993; 54:430 6.
46. 4-induced bronchoconstiction in the human. Am Rev Respir Dis 1991; 144:617 21.
47. Dahlen B, Zetterstrom O, Bjorck T, Dahlen S-E. The leukotriene-antagonist ICI-204. 219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Respir J 1994; 7:324 31.
48. Nathan RA, Glass M, Minkwitz MC. Inhaled ICI; 204:219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. Chest 1994; 105:483 8.
49. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI; 204:219 on allergen induced bronchoconstriction and airways hyperreactivity in atopic subjects. Lancet 1991; 337:690 4.
50. 4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol 1992; 90:193 201.
51. Taniguchi Y, Gamura G, Honma M et al. The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol 1993; 92:507-12.
52. Hui K, Taylor I, Taylor G et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991; 46:184 9.
53. 4-receptor antagonist. Am Rev Respir Dis 1992; 145:746-9.
54. 4 receptor antagonist ICI; 204:219 against exercise-induced asthma. Am Rev Respir Dis 1993; 147:1413-8.
55. 4-receptor antagonist N Engl J Med 1991; 323:1736-9.
56. Robuschi M, Riva E, Fuccella WM et al. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F;104:353) A double-blind study vs disodium cromoglycate and placebo. Am Rev Respir Dis 1992; 145: 1285 8.
57. Meltzer SS, Rechsteiner EA, Johns MA, Cohn J, Bleecker ER. Inhibition of exercise-induced asthma by zileuton, a 5-lipoxygenase inhibitor (abstract). Am J Respir Crit Care Med 1994; 149:A215.
58. Mann JS, Robinson C, Sheridan AQ et al. Effect of inhaled piriprost (U-60, 257) a novel leukotriene inhibitor, on allergen and exercise induced bronchoconstriction in asthma. Thorax 1986; 41:746-52.
59. 4-receptor antagonist, ICI; 204:219, on cold-air-induced bronchoconstriction in patients with asthma (abstract). J Allergy Clin Immunol 1994; 93:295.
60. Israel E, Juniper EF, Callaghan JT et al. Effect of a leukotriene antagonist, LY 171883, on cold air-induced bronchoconstriction in asthmatics. Am Rev Respir Dis 1989; 140:1348-53.
61. Israel E, Dermarkarian R, Rosenbeg M et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990; 323:1769-70.
62. Kemp JP, Dockhorn RJ, Busse WW, Van As A. Prolonged effect of inhaled salmeterol against exercise-induced bronehospasm. Am J Respir Crit Care Med 1994; 150: 1612-5.
63. 4 release from activated neutrophils. Proc Natl Acad Sci. USA 1983; 80:4349 53.
64. Yamamoto H, Nagata M, Kuramitsu K et al. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am J Respir Crit Care Med 1994; 150: 254-7.
65. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SKF; 104:353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991; 144:957 8.
66. Dahlen B, Margolskee DJ, Zetterstrom O, Dahlen S-E. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 1993; 48:1205-10.
67. Israel E, Fischer AR, Rosenberg MA et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148:1447-51.
68. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150:618 23.
69. Spector S, Miller CJ, Glass M. 13-week dose response study with Accolate™ (zafirlukast) in patients with mild-to-moderate asthma (abstract). Am J Resp Crit Care Med 1995; 151:A379.
70. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991; 337:1062-3.
71. Israel E, Rubin P, Kemp J et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119:1059-66.
72. Israel E, Cohn J, Dube L, Drazen J, Group ZS. Effects of zileuton treatment on chronic stable asthma: results of a 13-week, double-blind, placebo-controlled trial (abstract). J Allergy Clin Immunol 1994; 93:295.
73. 4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis 1992; 146:358 63.
74. Lockey RF, Lavins BJ, Snader L. Effects of 13 weeks of treatment with ICI; 204:219 (Accolate™) in patients with mild-to-moderate asthma (abstract). J Allergy Clin Immunol 1995; 95:350.
75. Chen X-S, Sheller JR, Johnson EN, Funk CD. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 1994; 372:179 82.